-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Endurant Capital Management LP Buys Shares of 52,400 Galapagos NV (NASDAQ:GLPG)
Endurant Capital Management LP Buys Shares of 52,400 Galapagos NV (NASDAQ:GLPG)
Endurant Capital Management LP bought a new stake in shares of Galapagos NV (NASDAQ:GLPG – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 52,400 shares of the biotechnology company's stock, valued at approximately $3,250,000. Galapagos accounts for 0.9% of Endurant Capital Management LP's investment portfolio, making the stock its 28th biggest position. Endurant Capital Management LP owned 0.08% of Galapagos at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Calamos Advisors LLC purchased a new position in shares of Galapagos during the 1st quarter valued at $655,000. Bank of America Corp DE grew its holdings in shares of Galapagos by 346.2% during the 4th quarter. Bank of America Corp DE now owns 39,012 shares of the biotechnology company's stock valued at $2,151,000 after acquiring an additional 30,269 shares in the last quarter. Prelude Capital Management LLC grew its holdings in shares of Galapagos by 32.2% during the 1st quarter. Prelude Capital Management LLC now owns 29,760 shares of the biotechnology company's stock valued at $1,846,000 after acquiring an additional 7,255 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Galapagos by 20.0% during the 1st quarter. Great Point Partners LLC now owns 360,000 shares of the biotechnology company's stock valued at $22,327,000 after acquiring an additional 60,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Galapagos by 11.2% during the 4th quarter. Renaissance Technologies LLC now owns 56,600 shares of the biotechnology company's stock valued at $3,120,000 after acquiring an additional 5,700 shares in the last quarter. 19.48% of the stock is owned by institutional investors and hedge funds.
Get Galapagos alerts:Analyst Upgrades and Downgrades
Several research firms have recently commented on GLPG. Jefferies Financial Group cut shares of Galapagos from a "hold" rating to an "underperform" rating in a report on Monday, July 25th. Morgan Stanley cut shares of Galapagos from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $80.00 to $61.00 in a report on Friday. Finally, Royal Bank of Canada decreased their price objective on shares of Galapagos from $62.00 to $55.00 in a report on Monday, August 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $62.75.
Galapagos Trading Up 8.0 %
Shares of NASDAQ:GLPG opened at $51.99 on Tuesday. Galapagos NV has a 1 year low of $46.41 and a 1 year high of $72.11. The firm has a fifty day moving average price of $52.71 and a 200 day moving average price of $57.46.Galapagos (NASDAQ:GLPG – Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.48. The firm had revenue of $146.62 million during the quarter, compared to analyst estimates of $95.44 million. Galapagos had a negative net margin of 16.90% and a negative return on equity of 3.02%. As a group, research analysts anticipate that Galapagos NV will post -3.23 earnings per share for the current year.
Galapagos Company Profile
(Get Rating)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
Featured Articles
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
Endurant Capital Management LP bought a new stake in shares of Galapagos NV (NASDAQ:GLPG – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 52,400 shares of the biotechnology company's stock, valued at approximately $3,250,000. Galapagos accounts for 0.9% of Endurant Capital Management LP's investment portfolio, making the stock its 28th biggest position. Endurant Capital Management LP owned 0.08% of Galapagos at the end of the most recent quarter.
根据耐久资本管理有限公司提交给美国证券交易委员会的最新表格13F文件,该公司在第一季度购买了加拉帕戈斯公司(GLPG-GET Rating)的新股。该基金购买了52,400股这家生物技术公司的股票,价值约3,250,000美元。加拉帕戈斯占耐久资本管理公司投资组合的0.9%,使该股成为其第28大头寸。截至最近一个季度末,耐久资本管理有限公司拥有加拉帕戈斯0.08%的股份。
Other large investors also recently added to or reduced their stakes in the company. Calamos Advisors LLC purchased a new position in shares of Galapagos during the 1st quarter valued at $655,000. Bank of America Corp DE grew its holdings in shares of Galapagos by 346.2% during the 4th quarter. Bank of America Corp DE now owns 39,012 shares of the biotechnology company's stock valued at $2,151,000 after acquiring an additional 30,269 shares in the last quarter. Prelude Capital Management LLC grew its holdings in shares of Galapagos by 32.2% during the 1st quarter. Prelude Capital Management LLC now owns 29,760 shares of the biotechnology company's stock valued at $1,846,000 after acquiring an additional 7,255 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Galapagos by 20.0% during the 1st quarter. Great Point Partners LLC now owns 360,000 shares of the biotechnology company's stock valued at $22,327,000 after acquiring an additional 60,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Galapagos by 11.2% during the 4th quarter. Renaissance Technologies LLC now owns 56,600 shares of the biotechnology company's stock valued at $3,120,000 after acquiring an additional 5,700 shares in the last quarter. 19.48% of the stock is owned by institutional investors and hedge funds.
其他大型投资者最近也增持或减持了该公司的股份。Calamos Advisors LLC在第一季度购买了加拉帕戈斯股票的新头寸,价值65.5万美元。第四季度,美国银行(Bank Of America Corp DE)持有的加拉帕戈斯股票增加了346.2%。美国银行(Bank Of America Corp DE)目前持有39,012股这家生物技术公司的股票,价值2,151,000美元,此前该公司在上季度增持了30,269股。Prelude Capital Management LLC在第一季度持有的加拉帕戈斯股票增加了32.2%。Prelude Capital Management LLC现在拥有29,760股这家生物技术公司的股票,价值1,846,000美元,上个季度又收购了7,255股。Great Point Partners LLC在第一季度持有的加拉帕戈斯股票增加了20.0%。Great Point Partners LLC现在拥有360,000股这家生物技术公司的股票,价值22,327,000美元,在上个季度又购买了60,000股。最后,复兴科技有限责任公司在第四季度增持了11.2%的加拉帕戈斯股票。复兴科技有限责任公司在上个季度增持了5,700股后,现在持有这家生物技术公司56,600股股票,价值3,120,000美元。19.48%的股票由机构投资者和对冲基金持有。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several research firms have recently commented on GLPG. Jefferies Financial Group cut shares of Galapagos from a "hold" rating to an "underperform" rating in a report on Monday, July 25th. Morgan Stanley cut shares of Galapagos from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $80.00 to $61.00 in a report on Friday. Finally, Royal Bank of Canada decreased their price objective on shares of Galapagos from $62.00 to $55.00 in a report on Monday, August 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $62.75.
几家研究公司最近对GLPG发表了评论。在7月25日星期一的一份报告中,杰富瑞金融集团将加拉帕戈斯的股票评级从持有下调至表现不佳。摩根士丹利在周五的一份报告中将加拉帕戈斯股票的评级从增持下调至持平,并将该公司的目标价从80美元下调至61美元。最后,加拿大皇家银行在8月8日星期一的一份报告中将加拉帕戈斯股票的目标价从62.00美元下调至55.00美元。一名分析师将该股评级为卖出,五名分析师给予持有评级,两名分析师给予该股买入评级。根据MarketBeat.com的数据,该公司目前的普遍评级为持有,平均目标价为62.75美元。
Galapagos Trading Up 8.0 %
加拉帕戈斯股市上涨8.0%
Galapagos (NASDAQ:GLPG – Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.48. The firm had revenue of $146.62 million during the quarter, compared to analyst estimates of $95.44 million. Galapagos had a negative net margin of 16.90% and a negative return on equity of 3.02%. As a group, research analysts anticipate that Galapagos NV will post -3.23 earnings per share for the current year.
加拉帕戈斯(纳斯达克代码:glpg-Get Rating)最近一次发布收益报告是在8月4日星期四。这家生物技术公司公布了本季度每股收益(0.31美元),比分析师普遍预期的0.79美元高出0.48美元。该公司本季度营收为1.462亿美元,而分析师预期为9544万美元。加拉帕戈斯的净利润率为负16.90%,股本回报率为负3.02%。研究分析师预计,作为一个整体,加拉帕戈斯公司本年度的每股收益将达到3.23美元。
Galapagos Company Profile
加拉帕戈斯公司简介
(Get Rating)
(获取评级)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
加拉帕戈斯公司是一家综合性生物制药公司,从事各种药物的发现、开发和商业化,以满足高度未得到满足的医疗需求。其流水线产品包括非戈替尼,一种JAK1抑制剂,正处于临床试验的不同阶段,用于治疗类风湿性关节炎、克罗恩病、溃疡性结肠炎、小肠CD、瘘管性CD、强直性脊柱炎、牛皮癣关节炎和葡萄膜炎。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- 免费获取StockNews.com关于加拉帕戈斯的研究报告(GLPG)
- 这些股息获得者值得在你的投资组合中占有一席之地吗?
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别,但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
接受加拉帕戈斯日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对加拉帕戈斯和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧